India Home Loans (530979)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value ₹28.60 covers most of the ₹33.43 share price; P/B of 1.17 limits downside only if asset quality holds.
• Sales growth is 0%, meaning the top line is stable at ₹3 Cr in the latest quarter rather than shrinking.
• Current price is closer to the 52-week low ₹24.80 than the high ₹47.54, so much of the market's enthusiasm has already drained.

Concerns

• P/E of 389.54 and latest quarter net profit of ₹0 Cr make the earnings story nearly nonexistent.
• Profit growth is -87.50% and Piotroski F-Score is 3/9, pointing to serious financial deterioration.
• ROE of 0.25% is far below any acceptable return on shareholders' money.
• No dividend and zero profit growth provide no compensation for the risk of a small housing finance company.

AI Analysis

At first glance, a housing finance company selling at ₹33.43 with a book value of ₹28.60 looks like the kind of stock Graham would screen: P/B of only 1.17. But the old rule is that price is what you pay, quality is what you get. Here quality is missing. The trailing P/E is 389.54, and the latest quarter reports sales of just ₹3 crore and net profit of ₹0 crore. Profit growth has collapsed by 87.50%, sales growth is flat at 0%, and return on equity is 0.25%—money in the bank would do better. A Piotroski F-score of 3 out of 9 reinforces the message: financial health is deteriorating. No dividend means the investor receives no cash while waiting. This is a tiny ₹48 crore market cap company, and a housing finance business requires capital, discipline, and credit quality to earn a decent return. With near-zero profit, there is no cushion for losses, and the modest P/B premium offers little protection if book value erodes. The 52-week range of ₹24.80 to ₹47.54 tells me the market has already lost enthusiasm. I see no moat, no pricing power, no growth, and no evidence of a durable competitive advantage. At this price, I am not being invited to own a wonderful business at a fair price; I am being asked to buy a weak business at a book-value multiple. That can be an asset play if the book is solid and management can engineer a turnaround, but there is no evidence yet. In investing, you make your money by identifying improvement before the financial statements prove it. Here the statements show the opposite. I would wait for higher ROE, positive net profit, and a longer track record of stability. Until then, this belongs on the watch list, not in the portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer